The lethal activity and repair inhibition capacity of 1-(2-chloroethyl)-3-(2,6-dioxo-3-piperidyl)-1-nitrosourea B. DrewinkoL. -Y. Yang Preclinical Pages: 197 - 202
Structure-activity relationship of 1-propargyl-5-halopyrimidin-2-ones John M. DornishReidar Oftebro Preclinical Pages: 203 - 211
Correlation of the structure of amino-substituted anthraquinones to cytotoxicity in cultured Chinese hamster cells Bruce F. KimlerC. C. ChengMary L. Barnes Preclinical Pages: 213 - 218
Pharmacokinetic study of methyl glyoxal-bis-guanylhydrazone (methyl-GAG) Milan SlavikThomas ClouseRobert C. Eschbach Preclinical Pages: 219 - 224
Spirogermanium: A new investigational drug of novel structure and lack of bone marrow toxicity Milan SlavikOscar BlancJoan Davis Clinical Pages: 225 - 234
Methyl-glyoxal bis guanyl hydrazone (methyl-GAG, MGBG) in lymphoma and Hodgkin's disease William A. T. Knight IIICarol FabianCharles A. Coltman Jr. Clinical Pages: 235 - 237
A Phase II study of Bruceantin (NSC-165, 563) in advanced malignant melanoma James C. ArseneauJanet M. WolterJohn C. Ruckdeschel Clinical Pages: 239 - 242
Effect of 2,3-dihydro-1H-imidazo [1,2-b]pyrazole (IMPY) on the metabolism of human red cells Arthur L. Sagone Jr.James A. NeidhartRose Marie Husney Clinical Pages: 243 - 248
The treatment of acute leukemia with continuous infusion L-Alanosine James K. WeickBill L. TranumFrancis S. Morrison Clinical Pages: 249 - 252
Characterization of the pharmacokinetics of bisantrene (NSC-337766) John G. KuhnThomas M. LuddenDaniel D. Von Hoff Clinical Pages: 253 - 258